Anti-APP Antibody, clone 1F22 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone IF22 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects amyloid precursor protein (APP). It targets an epitope within the extracellular domain in the N-terminal region.

GST/His-tagged recombinant fragment corresponding to 150 amino acids from the N-terminal region of human Amyloid Precursor Protein (APP).

Anti-APP, clone 1F22 ZooMAb, Cat. No. ZRB1516, is a recombinant Rabbit monoclonal antibody that specifically targets Amyloid Precursor Protein and is tested for use in Affinity Binding Assay, Immunohistochemistry (Paraffin), and Western Blotting.

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected APP in human hippocampus and SH-SY5Ycell lysates.

Immunohistochemistry (Paraffin) Analysis: A 1:200 dilution from a representative lot detected APP in human brain, mouse brain and rat brain tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound human recombinant APP protein with a KD of 9.5 x 10-8 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Amyloid-beta precursor protein (UniProt: P05067; also known as APP, ABPP, APPI, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, CVAP, PreA4, Protease nexin-II, PN-II) is encoded by the APP (also known as A4, AD1) gene (Gene ID: 351) in human. APP undergoes extensive post-translational modification including glycosylation, phosphorylation, and tyrosine sulfation, as well as many types of proteolytic processing to generate peptide fragments. APP is proteolytically processed under normal cellular conditions by alpha-secretase or beta-secretase to generate and release soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. In Alzheimer s disease processing of C99 generates amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42) that form amyloid plaques. Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity. They bind transient metals such as copper, zinc and iron. APP can also be cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either caspase-6, -8 or -9 results in the production of the neurotoxic C31 peptide and the increased production of beta-amyloid peptides. In addition to its obvious role in Alzheimer′s disease, the most-substantiated role for APP is in synaptic formation and repair. Its expression is upregulated during neuronal differentiation and after neural injury. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

0.3 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.